Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan vs Losartan in Diabetic Nephropathy
NCT00362960Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2003
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of olmesartan in diabetic nephropathy (DN) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in total urinary protein excretion. Started May 2003; status: completed.
02
Drugs
olmesartan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00362960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362960.